Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort

Clements, Matthew; Atkinson, Thomas M.; Dalbagni, Guido; Li, Yuelin; Herr, Harry W.; Donat, S. Machele; Sandhu, Jaspreet S.; Sjöberg, Daniel; Tin, Amy; Rapkin, Bruce D.; Bochner, Bernard H.

doi:10.1016/j.eururo.2021.09.018

Cited by 39 publications

(33 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since stoma is more likely to cause alteration of body appearance, it is a reasonable result. Comparable findings were previously reported by Clements et al 15 , showing that the body images of patients with continent diversion were better than those with ileal conduit diversion in longitudinal data of 411 cohorts. Most likely, our sample size undermined the statistical power to detect the difference.…”

Section: Discussionsupporting

confidence: 89%

Validation of the Japanese version of the Body Image Scale for bladder cancer patients

Sato

Osawa

Abe

et al. 2022

Sci Rep

View full text Add to dashboard Cite

The Body Image Scale (BIS) is a 10-item tool that measures the body images of cancer patients. This study aims to validate the Japanese version of the BIS for bladder cancer patients. A multicenter cross-sectional survey was used to identify the participants, which included Japanese bladder cancer patients. The percentage of missing responses, internal consistency, and known-group validity were evaluated. The correlations between the BIS and two HRQOL instruments (the Bladder Cancer Index and the SF-12) were assessed to determine convergent validity. Among 397 patients, 221 patients were treated by transurethral resection of bladder tumor (TURBT) endoscopically, 49 patients underwent cystectomy with neobladder, and 127 patients underwent cystectomy involving stoma. The percentage of missing responses in the BIS ranged from 8.1 to 15.6%. Cronbach's α coefficient was 0.924. Higher BIS scores indicate negative body image, and the median BIS score for patients with native bladders after TURBT (0.5) was significantly lower than those of the patients with neobladder (4.0) and stoma formation (7.0), which indicated the discriminatory ability of the BIS. Each domain of the Bladder Cancer Index and the role summary score of the SF-12 correlated to the BIS scores, which confirmed the convergent validity. A range of BIS scores were identified among patients who reported similar physical summary scores and mental summary scores of the SF-12. This study confirmed the reliability and validity of the Japanese version of the BIS for bladder cancer patients.

show abstract

Section: Discussionsupporting

confidence: 89%

Validation of the Japanese version of the Body Image Scale for bladder cancer patients

Sato

Osawa

Abe

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In the base case analysis, ddMVACx6 was associated with 0. 34 Clements 2022, 35 Parekh 2018, 36 4). Correspondingly, at a willingness to pay threshold of $100,000, ddMVACx6 was found to be more cost-effective than GCx4 at 5 years.…”

Section: Base Casementioning

confidence: 99%

Comparative cost‐effectiveness of neoadjuvant chemotherapy regimens for muscle‐invasive bladder cancer: Results according to VESPER data

Joyce

Wymer

Sharma

et al. 2022

Cancer

View full text Add to dashboard Cite

Background:The VESPER trial demonstrated improved progression-free (PFS) and (preliminarily) overall survival (OS) with six cycles of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVACx6) versus four cycles of gemcitabine and cisplatin (GCx4) before radical cystectomy (RC) for muscleinvasive bladder cancer (MIBC), but with increased toxicity. This study compares the cost-effectiveness of these regimens. Methods:A cost-effectiveness analysis of neoadjuvant ddMVACx6 and GCx4 was performed using a decision-analytic Markov model with 5-year, 10-year, and lifetime horizons. Probabilities were derived from reported VESPER data. Utility values were obtained from the literature. Primary outcomes were effectiveness measured in quality-adjusted life years (QALY) and incremental cost-effectiveness ratio (ICER) with a willingness to pay threshold of $100,000 per QALY. One-way and probabilistic sensitivity analyses were performed to evaluate the robustness of the model.

show abstract

“…From 1995 to 2015, 5‐year mortality from bladder cancer declined and survival rates improved after RC, attributed to optimized surgical procedures integrated with improved perioperative care and systemic chemotherapy 41 . The first prospective, long‐term health‐related study documented favorable QoL after contemporary RC and different types of urinary diversion 42 …”

Section: Bladder Cancermentioning

confidence: 99%

“…41 The first prospective, longterm health-related study documented favorable QoL after contemporary RC and different types of urinary diversion. 42 Quality of surgery (and the surgeon) was first identified as an independent variable for survival in 2004. 43 Beginning in 1995, perioperative clinical care pathways, now referred to as enhanced recovery after surgery, was first initiated for cystectomy patients and then integrated with all major urological cancer procedures.…”

Section: Radical Cystectomy (Rc)mentioning

confidence: 99%

Genitourinary tumors

Herr

Sogani

Eastham

2022

Journal of Surgical Oncology

View full text Add to dashboard Cite

Memorial Sloan Kettering Cancer Center (MSK) has made many notable contributions to the scientific understanding and care of patients with common urologic cancers. Many of the advances represented paradigm shifts in management and established new standards of care. This review highlights the surgical procedures and treatment strategies originated and pioneered by urologic surgeons and colleagues at MSK during the past 50 years. K E Y W O R D S genitourinary surgical oncology, tumors 1 | INTRODUCTION Genitourinary (GU) neoplasms comprise biologically distinct tumors of the prostate, bladder, kidney, and testis. They account for 23% of all malignancies and 7% of cancer deaths. An estimated 438 580 new cases in men and women with these malignancies are diagnosed each year, with 65 980 (15%) dying of their disease. 1 From 1971 to 2019, age-standardized cancer mortality has declined for prostate (−11.9), bladder (−1.5) and kidney (−0.9) cancers, 2 due in part to improvements in earlier detection and treatments. Testis cancer survival rates have remained stable at over 90%. GU tumors may be highly malignant or indolent and slow growing. Surgery is essential for diagnosis, staging, and cure. Based on an evolving understanding of tumor biology, the over-arching principle is to aggressively treat those patients who need it and avoid unnecessary treatment for those who do not. Over the past 50 years, Memorial Sloan Kettering Cancer Center (MSK) devised treatment strategies for GU tumors that shifted previous management paradigms and established new standards of care. Although many individuals working in multiple institutions worldwide have contributed to improved outcomes for patients with GU tumors, this review highlights significant surgical procedures and treatment strategies originated and pioneered by urologic surgeons and colleagues at MSK.

show abstract

Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort

Cited by 39 publications

References 38 publications

Validation of the Japanese version of the Body Image Scale for bladder cancer patients

Validation of the Japanese version of the Body Image Scale for bladder cancer patients

Comparative cost‐effectiveness of neoadjuvant chemotherapy regimens for muscle‐invasive bladder cancer: Results according to VESPER data

Genitourinary tumors

Contact Info

Product

Resources

About